Mark‘s current work is focused on the evaluation of molecular and phenotypic evidence supporting a target-indication pair. Mark’s former GSK projects have included pharma pipeline cost analysis, drug repositioning, mRNA expression analysis and structure-based antibody humanization. He obtained his PhD in Chemistry from Penn State (1987) and his S.B. in Chemistry from M.I.T. (1982).
|Part 1: Educating on the open targets platform|
Open Targets is an innovative, large-scale, multi-year, public-private partnership that uses human genetics and genomics data for systematic drug target identification and prioritisation.
Visit the Open Targets Platform which provides an integration of public domain data to enable target identification and prioritisation.
Generating and interpreting the data required to identify a good drug target demands a diverse set of skills, backgrounds, evidence types and technologies, which do not exist today in any single entity. Open Targets brings together expertise from four complementary institutions to systematically identify and prioritise targets from which safe and effective medicines can be developed.
Our goals are to:
Integrating your expertise and AI approaches into the Open Targets platform